(Press-News.org) A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV in the first large-scale clinical study to test a primary cardiovascular prevention strategy in this population. A planned interim analysis of data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found that participants who took pitavastatin calcium, a daily statin, lowered their risk of major adverse cardiovascular events by 35% compared with those receiving a placebo. Adverse drug events observed in the study were like those in the general population taking statin therapy. The interim analysis was sufficiently compelling that the study’s independent Data Safety and Monitoring Board (DSMB) recommended it be stopped early given adequate evidence of efficacy. The NIH accepted the DSMB recommendations.
REPRIEVE began in 2015 and enrolled 7,769 volunteers who were 40 to 75 years of age, of whom more than 30% were women. REPRIEVE volunteers were all taking antiretroviral therapy, with CD4+ cell counts greater than 100 cells/mm3 of blood at enrollment, and had low-to-moderate traditional cardiovascular disease risk that would not typically be considered for statin treatment. The trial was conducted in 12 countries in Asia, Europe, North America, South America and Africa.
The REPRIEVE study is primarily supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI) with additional funding from the NIH Office of AIDS Research. The study was conducted by the AIDS Clinical Trials Group (ACTG).
Decades of research and advances in HIV treatment have drastically reduced AIDS-related complications and deaths. As people with HIV live longer, premature heart disease and other chronic conditions have emerged as leading causes of morbidity and mortality, contributing to persistent gaps in lifespan between people with HIV and the broader population.
“The REPRIEVE study reflects the evolution of HIV science, and progress from focusing mostly on approaches to treat and control the virus to finding ways to improve the overall health of people living with HIV,” said acting NIAID Director Hugh Auchincloss, M.D. “These new data suggest that a common cholesterol-lowering medicine could substantially improve cardiovascular outcomes in people with HIV.”
Statins are a class of medicines routinely prescribed to lower cholesterol and are known to prevent cardiovascular disease in those at risk in the general population. It was not clear if statins would have the same effect in people living with HIV and who have premature cardiovascular disease despite having low-to-moderate traditional risk. In the REPRIEVE trial, participants were randomly assigned to receive a daily dose of 4 mg of pitavastatin or placebo. They were monitored for major adverse cardiovascular events and adverse reactions to pitavastatin, which is considered safe for use with all prescribed antiretroviral therapy regimens.
The study’s DSMB met at planned intervals throughout the study to review safety and efficacy data. In its most recent meeting, the DSMB determined that the benefits of daily pitavastatin use outweighed any risks and recommended that the study terminate early, and that a full data collection be conducted across sites for final analysis. Study participants are being notified of the findings and will continue to be monitored for several months. Study results from the DSMB review are expected to be published in the coming weeks.
“These latest findings represent the culmination of an unprecedented eight-year effort to generate evidence that can help clinicians better support the unique cardiovascular health needs of people living with HIV,” said NHLBI Director Gary H. Gibbons, M.D. “REPRIEVE is important because there are limited existing interventions to help prevent adverse cardiovascular outcomes in this population.”
The REPRIEVE study was funded by a grant to the Massachusetts General Hospital and led by Steven Grinspoon, M.D, professor of medicine at Harvard University, endowed chair in Neuroendocrinology and Metabolism and chief of the metabolism unit at Massachusetts General Hospital, who directed the study’s Clinical Coordinating Center. Pamela Douglas, M.D., the Ursula Geller Professor of Research in Cardiovascular Diseases in the Duke University Department of Medicine, was co-principal investigator of the Clinical Coordinating Center. Michael T. Lu, M.D., co-director of the Massachusetts General Hospital Cardiovascular Imaging Research Center, and Heather Ribaudo, Ph.D., a principal research scientist at the Center for Biostatistics in AIDS Research and the Department of Biostatistics at Harvard University, served as leads of the REPRIEVE study’s Data Coordinating Center. The study was conducted by the NIAID-funded ACTG. Additional implementation support was provided by the London-based NEAT ID Foundation, Kowa Pharmaceuticals America, Inc., Gilead Sciences, Inc. and Viiv Healthcare.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®
END
TAMPA, Fla. (April 11, 2023) – After lightning struck a tree in a New Port Richey neighborhood, a University of South Florida professor discovered the strike led to the formation of a new phosphorus material. It was found in a rock – the first time in solid form on Earth – and could represent a member of a new mineral group.
“We have never seen this material occur naturally on Earth – minerals similar to it can be found in meteorites and space, but we've never seen this exact material anywhere,” said geoscientist Matthew Pasek.
In a recent study published in Communications Earth & Environment, Pasek examines ...
Natural gas supplies 32% of all primary energy in the United States, its share of electricity generation having nearly doubled from 2008 to 2021. The cross-country natural gas pipeline system used to be powered mainly by natural gas, but recently has switched in places to electric power. The natural gas pipeline system has generally been much more reliable than the electric power system. The new dependence on electricity has created a vulnerability during hurricanes and other events that can take out electric power, since lack of natural gas may in turn cause gas-powered electric ...
Researchers at Baylor College of Medicine and collaborating institutions report in the journal Nature Communications how a mutation in the enzyme SKD3 can cause a form of a genetic disease known as 3-methylglutaconic aciduria (MGCA7). MGCA7 is an inborn error of metabolism associated with variable neurologic deficits and an abnormally low number of immune cells called neutrophils in the blood. The latter condition, known as neutropenia, can lead to increased susceptibility to infection and can also develop into leukemia, as well as early death in infants.
“SKD3 is essential to protein quality control in animal cells. It removes damaged proteins in structures or organelles ...
Key Takeaways:
Consumers differ in the way that they shop: some “showroom” by figuring out what they want at one kind of retail outlet and buying elsewhere; others conduct deep research and buy where they first find what they like; and other kinds of consumers are less particular and conduct only fairly limited research.
Consumers who are less choosy may shop at stores that have fewer selections, as long as they can pay a lower price for what they buy. This is the one group of consumers most likely to influence price.
BALTIMORE, MD, April 11, 2023 – It’s ...
WASHINGTON — Researchers have developed a new chip-sized microwave photonic filter to separate communication signals from noise and suppress unwanted interference across the full radio frequency spectrum. The device is expected to help next-generation wireless communication technologies efficiently convey data in an environment that is becoming crowded with signals from devices such as cell phones, self-driving vehicles, internet-connected appliances and smart city infrastructure.
“This new microwave filter chip has the potential to improve wireless communication, such as 6G, leading to faster internet connections, better overall communication ...
In Switzerland, one in three employees suffers from workplace stress. Those affected often don’t realise that their physical and mental resources are dwindling until it’s too late. This makes it all the more important to identify work-related stress as early as possible where it arises: in the workplace.
Researchers at ETH Zurich are now taking a crucial step in this direction. Using new data and machine learning, they have developed a model that can tell how stressed we are just from the way we type and use our mouse.
And there’s more: “How we type on our keyboard and move our mouse seems to be a better predictor of how stressed ...
Among Indigenous, rural non-industrial populations inhabiting the tropical forests of lowland Bolivia, researchers report, there appears to be an optimal balance between levels of food consumption and exercise that maximizes healthy brain aging and reduces the risk of disease.
“We hypothesize that energy gain from food intake was positively associated with late life brain health in the physically active, food-limited world of our ancestors, but that obesity and other manifestations of a Western lifestyle ...
Despite the success of vaccines for preventing COVID-19, and of drugs for treating the disease, outcomes for severely ill patients admitted to the hospital remains poor. Identifying new therapies for severe COVID-19 remains a high priority and one in which Vanderbilt University Medical Center is taking a leading role.
A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters ...
New research by the University of Warwick has identified characteristics of aggressive driving – which impact both road users and the transition to self-driving cars of the future.
In the first study to systematically identify aggressive driving behaviours, scientists have measured the changes in driving that occur in an aggressive state. Aggressive drivers drive faster and with more mistakes than non-aggressive drivers – putting other road users at risk and posing a challenge to researchers working on self-driving car technology.
The research comes as a leading Detective Chief Superintendent, Andy ...
Patients treated with blood pressure-lowering drugs can experience much greater improvements from a change of medication than from doubling the dose of their current medication. This is shown by a new study from Uppsala University, published in the Journal of the American Medical Association (JAMA). In this study, 280 patients tested four different blood pressure-lowering drugs over the course of a year.
“The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient’s current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is ...
